Orphan drugs in Australia

被引：6
|
作者：
Herkes, Geoffrey K. [1 ,2 ,3 ]
机构：
[1] Royal North Shore Hosp, Dept Neurol, St Leonards, NSW, Australia
[2] Univ Sydney, Kolling Inst, Med, Sydney, NSW, Australia
[3] Advisory Comm Prescript Med Therapeut Goods Adm, Canberra, ACT, Australia
来源：
EXPERT OPINION ON ORPHAN DRUGS | 2016年 / 4卷 / 12期
关键词：
Orphan drug program; review; rare diseases; oncology;
D O I：
10.1080/21678707.2016.1257383
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1195 / 1197
页数：3
相关论文
共 50 条
  • [21] Rare diseases and orphan drugs: Latvian story
    Logviss, Konstantins
    Krievins, Dainis
    Purvina, Santa
    ORPHANET JOURNAL OF RARE DISEASES, 2014, 9
  • [22] Orphan drugs policies: a suitable case for treatment
    Michael Drummond
    Adrian Towse
    The European Journal of Health Economics, 2014, 15 : 335 - 340
  • [23] Estimating the clinical cost of drug development for orphan versus non-orphan drugs
    Jayasundara, Kavisha
    Hollis, Aidan
    Krahn, Murray
    Mamdani, Muhammad
    Hoch, Jeffrey S.
    Grootendorst, Paul
    ORPHANET JOURNAL OF RARE DISEASES, 2019, 14 (1)
  • [24] EU marketing authorization review of orphan and non-orphan drugs does not differ
    Putzeist, M.
    Mantel-Teeuwisse, A. K.
    Llinares, J.
    Gispen-De Wied, C. C.
    Hoes, A. W.
    Leufkens, H. G. M.
    DRUG DISCOVERY TODAY, 2013, 18 (19-20) : 1001 - 1006
  • [25] Orphan drugs: pricing, reimbursement and patient access
    Barak, Adam
    Nandi, Jyoti Shankar
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL AND HEALTHCARE MARKETING, 2011, 5 (04) : 299 - 317
  • [26] Orphan Drugs, Compounded Medication and Pharmaceutical Commons
    Hendrickx, Kim
    Dooms, Marc
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [27] Fair pricing of "old" orphan drugs: considerations for Canada's orphan drug policy
    Roberts, Eve A.
    Herder, Matthew
    Hollis, Aidan
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2015, 187 (06) : 422 - 425
  • [28] Authorization and Reimbursement of Orphan Drugs in an International Comparison
    Roll, K.
    Stargardt, T.
    Schreyoegg, J.
    GESUNDHEITSWESEN, 2011, 73 (8-9) : 504 - 514
  • [29] Market uptake of orphan drugs - a European analysis
    Picavet, E.
    Annemans, L.
    Cleemput, I.
    Cassiman, D.
    Simoens, S.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2012, 37 (06) : 664 - 667
  • [30] ORPHAN DRUGS: OVERVIEW AND REGULATORY REVIEW PROCESS
    Thaker, Z.
    Jethva, K.
    Bhatt, D.
    Zaveri, M.
    Deshpande, S.
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2019, 10 (02): : 505 - 518
12345